RxDoctor Payments Data

Sanjay Vyas, DO

Family Medicine · Greenwood, INNPI 1295708766

Payments from drug & device makers

$3,517in general payments, 2019–2025

Across 247 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$761
  • GSK$527
  • Amgen$332
  • Pfizer$230
  • AstraZeneca$202
  • Bayer$180
  • plus $1K from 31 others

What the payments were for

  • Food & beverage$3,504100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,517 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$190,891
Medicare patients
452
Services billed
11,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$97,035
JanuviaSitagliptin Phosphate62$70,137
JardianceEmpagliflozin29$38,354
XareltoRivaroxaban30$36,175
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$30,240
Breo ElliptaFluticasone/Vilanterol40$25,225
JanumetSitagliptin Phos/Metformin Hcl17$18,816
LinzessLinaclotide26$16,145
Atorvastatin Calcium1,101$7,781
FarxigaDapagliflozin Propanediol12$7,544
SynthroidLevothyroxine Sodium91$7,310
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,760
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen361$6,216
Omeprazole452$5,883
Gabapentin333$5,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$230$99,861114 claims
MerckJanuvia, Janumet$16$88,95379 claims
GSKTrelegy Ellipta, Breo Ellipta$527$55,46573 claims
Boehringer IngelheimJardiance$43$38,35429 claims
Johnson & JohnsonXarelto$132$36,17530 claims
AbbVieLinzess, Synthroid$761$23,456117 claims
AstraZenecaFarxiga$202$7,54412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Greenwood

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →